A Semmelweis Egyetem magyar budapesti orvos-egészségügyi felsőoktatási intézmény. Egészségtudományi szakegyetemként egyedülálló az országban; névadója Semmelweis Ignác. A több mint 250 éves egyetem három fő tevékenysége az oktatás, a kutatás-innováció és a gyógyítás.

During the past decade, Semmelweis University conducted 85 clinical trials. In the 10-year time frame, 85 clinical trials started and 36 clinical trials were completed, i.e. on average, 42.4% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 26 clinical trials were completed. i.e. 63.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Semmelweis University" #1 sponsor was "Boehringer Ingelheim" with 18 trials, followed by "Biotronik SE & Co. KG" with 13 trials sponsored, "Semmelweis University" with 12 trials sponsored, "Bayer" with 11 trials sponsored and "Abbott Medical Devices" with 11 trials sponsored. Other sponsors include 66 different institutions and companies that sponsored additional 64 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis University" #1 collaborator was "Eli Lilly and Company" with 5 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 2 trials as a collaborator, "Semmelweis University" with 2 trials as a collaborator, "Takeda" with 2 trials as a collaborator and "Academy of Finland" with 1 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 53 trials.

According to Clinical.Site data, the most researched conditions in "Semmelweis University" are "Heart Failure" (11 trials), "Atrial Fibrillation" (5 trials), "Idiopathic Pulmonary Fibrosis" (4 trials), "Acromegaly" (3 trials) and "Breast Cancer" (3 trials). Many other conditions were trialed in "Semmelweis University" in a lesser frequency.

Most popular intervention types in "Semmelweis University" are "Drug" (75 trials), "Device" (28 trials), "Other" (16 trials), "Procedure" (8 trials) and "Biological" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Empagliflozin" (5 trials), "Apixaban" (3 trials), "Cyclophosphamide" (3 trials) and "Apixaban matching placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Semmelweis University" are 118 trials for "All" genders, 7 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Semmelweis University". undefined are not yet recruiting, 16 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 80 completed trials in Semmelweis University, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Semmelweis University, 5 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 23 trials that are defined as “Not Applicable".